
Recent developments regarding multiple myeloma highlight advances in access to medications and funding. [Brazil] Tocantins has incorporated daratumumab into treatment, while [Portugal] the SNS has begun to fund new therapeutic combinations. The approval of medications such as Iberdoma [USA] and the expansion of the Melflufen monograph [USA] are also important milestones.
Made by MielomaAI On November 17, 2026, at 10:32, from recent news. May contain errors. View news →
Bispecific antibodies are given every week or every two weeks, for months, so the cost is counted per month. Public list prices (before discounts).
US monthly list price at launch (2022–2023), converted to euros.
| Medicine | USA (list price) | United Kingdom (per vial, excluding VAT) | Portugal |
|---|---|---|---|
| Teclistamab (Tecvayli) Johnson & Johnson | 35.740 €/mês · 321.209 €–357.401 € por tratamento | 929,87 € (10 mg) · 4.741,82 € (90 mg) | Confidential price |
| Elranatamab (Elrexfio) Pfizer | 37.550 €/mês · cerca de 298.588 € por tratamento | 2.946,26 € (44 mg) · 5.089,37 € (76 mg) | Confidential price |
| Talquetamab (Talvey) Johnson & Johnson | 40.717 €/mês · 244.300 €–325.733 € por tratamento | 391,57 € (3 mg) · 5.220,73 € (40 mg) | Confidential price |
| First line combinations | Per year: VRd about 166.298 €; DRd about 345.691 € | — | In the SNS, at no cost to the patient |
Sources: Source: Managed Healthcare Executive (Tecvayli) ↗ · Source: BioPharma Dive (Elrexfio) ↗ · Source: Fierce Pharma (Talvey) ↗ · Source: NICE TA1015 (teclistamab) ↗ · Source: NICE TA1023 (elranatamab) ↗ · Source: NICE TA1114 (talquetamab) ↗ · Source: Current Hematologic Malignancy Reports (1.ª linha) ↗
Amounts converted to euros: €1 = 1.1052 dollars and 6.1748 reais (European Central Bank reference rates of 13/11 and 09/11/2026) and 0.8336 pounds (market rate of 05/11/2026). The original amounts are in the sources. 2022–2023 prices may have risen since. Older medicines, such as lenalidomide, already have generics and cost much less.



Luciano Costa Shares His Top 10 Multiple Myeloma Abstracts at ASH 2026 / American Society of Hematology (ASH), ASH 2026, cancer care, cancer research

Ralph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.
All news → · Summaries created by MielomaAI; expand the article to read the original.
